A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 25,888 shares of RLMD stock, worth $9,837. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,888
Previous 88,775 70.84%
Holding current value
$9,837
Previous $266,000 68.8%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.3 - $4.36 $144,640 - $274,187
-62,887 Reduced 70.84%
25,888 $83,000
Q2 2024

Aug 09, 2024

BUY
$2.93 - $4.94 $157,537 - $265,608
53,767 Added 153.58%
88,775 $266,000
Q1 2024

May 13, 2024

SELL
$3.1 - $6.8 $346,831 - $760,790
-111,881 Reduced 76.17%
35,008 $163,000
Q4 2023

Feb 13, 2024

BUY
$2.45 - $4.22 $199,954 - $344,411
81,614 Added 125.03%
146,889 $608,000
Q3 2023

Nov 14, 2023

SELL
$2.48 - $3.79 $167,392 - $255,813
-67,497 Reduced 50.84%
65,275 $196,000
Q2 2023

Aug 11, 2023

SELL
$2.22 - $3.54 $400,494 - $638,626
-180,403 Reduced 57.6%
132,772 $327,000
Q1 2023

May 12, 2023

BUY
$2.24 - $4.76 $213,617 - $453,937
95,365 Added 43.78%
313,175 $708,000
Q4 2022

Feb 13, 2023

BUY
$2.17 - $35.84 $472,647 - $7.81 Million
217,810 New
217,810 $760,000
Q1 2022

May 13, 2022

SELL
$16.72 - $26.99 $240,767 - $388,656
-14,400 Closed
0 $0
Q4 2021

Feb 11, 2022

SELL
$16.93 - $26.82 $18,623 - $29,502
-1,100 Reduced 7.1%
14,400 $324,000
Q3 2021

Nov 12, 2021

BUY
$21.86 - $34.77 $338,830 - $538,935
15,500 New
15,500 $406,000

Others Institutions Holding RLMD

About RELMADA THERAPEUTICS, INC.


  • Ticker RLMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,608,500
  • Market Cap $10.9M
  • Description
  • Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...
More about RLMD
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.